Tyson Foods, Inc. vs Twist Bioscience Corp — how do they compare? Tyson Foods, Inc. trades at $53.35 (market cap $18.41B), while Twist Bioscience Corp trades at $161.93 (market cap $10.08B). The key difference: Tyson Foods, Inc. is the larger of the two by market cap, and Tyson Foods, Inc. pays a 3.9% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tyson Foods, Inc. for 76 Days and Twist Bioscience Corp for 27 Days on average.
| TSN | TWST | |
|---|---|---|
Market Cap | $18.41B | $10.08B |
Volume | 3,757,599 | 4,229,037 |
Sector | Consumer Staples | Health |
52-Week High | $68.75 | $205.00 |
52-Week Low | $50.47 | $25.45 |
Typical Hold Time | 76 Days | 27 Days |
Enterprise Value | $25.68B | $10.01B |
Dividend Yield | 3.9% | — |
Signals from Pluang's Aura AI — not financial advice
Tyson Foods (TSN) trades at $52.70, up 1.93% with mixed technical signals showing bullish overall but bearish moving averages. The company reported Q2 2026 EPS of $0.99 beating expectations, though revenue growth remains modest at 1.5%-2.0% for 2026. Analysts maintain a Buy consensus with $65.40 target, but recent news highlights investigations into guidance revisions and beef segment challenges.
Outlook remains cautious with upside potential from execution improvements, but risks include beef segment losses, margin pressure, and ongoing securities investigations. The stock offers value with low P/S of 0.33 and consistent dividends, but requires monitoring of operational turnaround and legal developments.
Twist Bioscience (TWST) trades at $162.43, up 4.36% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical signal with RSI at 29.02 indicating potential oversold conditions. Fundamentally, revenue growth continues (2025: $377M, 2026: $432M projected) but profitability remains elusive with negative margins. Recent partnership with Eli Lilly's TuneLab platform highlights strategic positioning in AI-driven drug discovery.
While analyst consensus favors Buy (73%), the stock trades above the $145.20 target, suggesting limited near-term upside. Key risks include persistent cash burn (-$44M net CF in 2025) and high valuation multiples (P/S: 21.5). The AI biotech partnership provides growth catalyst potential, but profitability timeline remains uncertain for investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →